|
22 Aug 2019 |
Fiasp® approved in Europe for the management of diabetes in adolescents and children aged one year and above
|
|
21 Aug 2019 |
Ra Pharmaceuticals Earns Clinical Development Milestone for Oral Macrocyclic Peptide Candidate Targeting Cardiovascular Indication Under Agreement with Merck
|
|
20 Aug 2019 |
Myovant Sciences Completes Patient Recruitment for Phase 3 SPIRIT 2 Study Evaluating Relugolix Combination Therapy in Women with Endometriosis
|
|
20 Aug 2019 |
Eiger Announces FDA Breakthrough Therapy Designation for Peginterferon Lambda for Treatment of Hepatitis Delta Virus Infection
|
|
15 Aug 2019 |
Mallinckrodt Announces Positive Top-Line Results from its Pivotal Phase 3 CONFIRM Trial of Terlipressin in Patients with Hepatorenal Syndrome Type 1 (HRS-1)
|
|
08 Aug 2019 |
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
|
|
07 Aug 2019 |
Rhythm Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Clinical Trials Evaluating Setmelanotide in POMC and LEPR Deficiency Obesities
|
|
07 Aug 2019 |
Jazz Pharmaceuticals Advances Recombinant Crisantaspase Development Program
|
|
06 Aug 2019 |
Inotrem Announces FDA Clearance of Investigational New Drug (IND) for the Phase IIB ASTONISH Trial in Septic Shock Patients to Demonstrate Nangibotide Efficacy
|
|
05 Aug 2019 |
INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer
|
|
05 Aug 2019 |
Antidote Therapeutics Progresses Optimization of the Nicotine-degrading Enzyme, NicA2, for Potential Use in Treating Nicotine Addiction
|
|
31 Jul 2019 |
Medicenna Selects its Lead Immuno-Oncology Clinical Candidate, MDNA19, from its IL-2 Superkine Platform
|
|
29 Jul 2019 |
Rhythm Pharmaceuticals Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for Setmelanotide for the Treatment of Bardet-Biedl Syndrome
|
|
25 Jul 2019 |
BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
|
|
24 Jul 2019 |
Synthorx Initiates Patient Dosing in Australia and Announces Clearance of IND in the U.S. for Lead Immuno-oncology Product Candidate, THOR-707
|
|
21 Jul 2019 |
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia
|
|
16 Jul 2019 |
Ambrx to receive milestone payment from Bristol-Myers Squibb for the initiation of Phase 1 Clinical Trial of a long-acting Relaxin derivative
|
|
16 Jul 2019 |
Synlogic Reports Positive Top-line Data from Phase 1/2a Study of SYNB1618 in Patients with Phenylketonuria and Guides to Next Phase of Development
|
|
11 Jul 2019 |
SOTIO Initiates First-In-Human Clinical Trial with IL-15 Superagonist SO-C101
|
|
09 Jul 2019 |
Dermata Therapeutics Announces Positive Results from a Phase 1 Clinical Trial of DMT410, A New Topical Delivery Mechanism for Botulinum Toxin
|
|
08 Jul 2019 |
Catalyst Biosciences Meets the Primary Endpoint of Reduction in Annualized Bleeding Rate in the Phase 2 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Patients with Hemophilia A or B with Inhibitors
|
|
08 Jul 2019 |
Aravive Announces Independent Data Monitoring Committee Recommends Continuation of Phase Ib Study of AVB-500 In Recurrent Platinum Resistant Ovarian Cancer After Review of First Two Cohorts of Patients
|
|
08 Jul 2019 |
New data show nonacog beta pegol (N9-GP) is effective and well tolerated for the prevention and treatment of bleeding in children with haemophilia B
|
|
08 Jul 2019 |
Interim Data Evaluating Elocta® for Immune Tolerance Induction in People With Inhibitors and Severe Haemophilia A Shared at ISTH 2019
|
|
08 Jul 2019 |
Takeda Unveil New Data from the PROPEL Study at ISTH 2019, Reinforcing the Potential Benefit for Personalized Prophylaxis with ADYNOVATE in Severe Hemophilia A
|
